Skip to main content

Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure

Medically reviewed by Carmen Pope, BPharm. Last updated on May 10, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 10, 2024 -- The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic heart failure, according to a study published online May 7 in The Journal of Heart and Lung Transplantation.

Christopher S. Almond, M.D., M.P.H., from the Stanford University School of Medicine in Palo Alto, California, and colleagues recruited children weighing 8 to 30 kg with severe systolic heart failure and failing optimal medical therapy from seven U.S. centers to describe the initial outcomes of the Jarvik 2015.

The researchers found that the median duration of Jarvik 2015 support was 149 days; all seven children survived: five, one, and one to transplant, recovery, and conversion to a paracorporeal device, respectively. In the setting of myocardial recovery, one patient experienced an ischemic stroke on day 53 of device support. One patient required extracorporeal membrane oxygenation for intractable ventricular arrhythmias and was transplanted from paracorporeal biventricular ventricular assist device support. At seven, 30, 90, and 180 days or time of explant, the median plasma-free hemoglobin was 19, 30, 19, and 30 mg/dL, respectively. All patients reached the primary feasibility endpoint of survival to 30 days without severe stroke or nonoperational device failure. With respect to participation in a full range of activities, patient-reported outcomes with the device were favorable. The study was suspended after consent of the eighth patient due to financial issues with the manufacturer.

"Among children implanted with the Jarvik 2015 LVAD, the median duration of support was 149 days and survival to heart transplant or recovery was favorable," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.